MedTrace Logo

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients

NCT02576314 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-03-19

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability, and efficacy of Sofosbuvir containing regimens in treatment-naive or treatment-experienced patients with HCV genotype 3 infection.

Conditions

  • Chronic Hepatitis C Infection

Interventions

DRUG

sofosbuvir and daclatasvir

Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60 mg tablet administered orally once daily.

DRUG

ledipasvir/sofosbuvir

Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally. once daily;

Sponsors & Collaborators

  • Beijing 302 Hospital

    collaborator OTHER

  • Humanity and Health Research Centre

    lead OTHER

Principal Investigators

  • George Lau, MD · Humanity and Health GI and Liver Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2017-12-31
Completion
2018-03-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02576314 on ClinicalTrials.gov